###begin article-title 0
Serum Concentration of Interleukin-6 Is Increased Both in Active and Remission Stages of Pemphigus Vulgaris
###end article-title 0
###begin p 1
Recommended by Yona Keisari
###end p 1
###begin p 2
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 2
###begin p 3
###xml 134 139 134 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 487 488 483 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 612 613 608 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 613 614 609 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 613 614 609 610 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>P</italic></sub>
###xml 623 624 619 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 682 687 678 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 698 707 690 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pemphigus</italic>
###xml 767 768 759 760 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 768 769 760 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S</italic>
###xml 768 769 760 761 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>S</italic></sub>
###xml 782 783 774 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 827 832 819 820 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 162 170 <span type="species:ncbi:9606">patients</span>
###xml 239 247 <span type="species:ncbi:9606">patients</span>
###xml 276 284 <span type="species:ncbi:9606">patients</span>
###xml 500 508 <span type="species:ncbi:9606">patients</span>
###xml 732 740 <span type="species:ncbi:9606">patients</span>
As most studies on pemphigus vulgaris (PV) pathogenesis concern its active stage, we aimed to evaluate the serum concentration of TNF-alpha, IL-1, and IL-6 in PV patients in clinical remission. The study group consisted of sera from 19 PV patients in active stage and from 24 patients in clinical remission. 19 sera taken from healthy subjects served as the controls. Serum IL-6 concentrations in PV active and PV remission group were significantly higher when compared to the controls (P < .05). In patients in active stage of PV, a significant correlation between serum IL-1 and IL-6 concentrations was found (rP = 0.46; P < .05). We also found a negative correlation between TNF-alpha level and pemphigus antibodies titer in the patients from the remission group (rS = -0.47303; P < .02). Our data suggest that IL-6 and TNF-alpha may be involved in maintaining immunological disturbances in remission stage of PV.
###end p 3
###begin title 4
1. INTRODUCTION
###end title 4
###begin p 5
###xml 144 153 144 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pemphigus</italic>
###xml 603 612 603 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pemphigus</italic>
###xml 787 788 787 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 986 991 986 987 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 1123 1132 1119 1128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pemphigus</italic>
###xml 1163 1168 1159 1160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 1228 1233 1220 1221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 1319 1320 1307 1308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 1321 1322 1309 1310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 1387 1392 1375 1376 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 1472 1481 1456 1465 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pemphigus</italic>
###xml 1494 1495 1478 1479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 1621 1622 1605 1606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 1624 1625 1608 1609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 398 406 <span type="species:ncbi:9606">patients</span>
###xml 454 462 <span type="species:ncbi:9606">patients</span>
###xml 1279 1287 <span type="species:ncbi:9606">patients</span>
###xml 1370 1374 <span type="species:ncbi:10090">mice</span>
Pemphigus is an autoimmune blistering disease, characterised by severe and chronic course. Based on clinical picture and profile of circulating pemphigus antibodies, two distinct forms of the disease are distinguished: pemphigus vulgaris (PV) and pemphigus foliaceus (PF). Transmembrane desmosomal proteins: desmoglein 1 (Dsg1) and desmoglein 3 (Dsg3) are pemphigus target antigens. In serum of PF patients, anti-Dsg1 antibodies are detected while in PV patients-antibodies are directed against Dsg3. However, in approximately 50% of the latter cases, also anti-Dsg1 antibodies may be found. Binding of pemphigus antibodies to the target antigens leads to the failure in adhesive function of desmogleins, and in consequence to disruption of desmosomes and thus acantholysis development [1]. Despite numerous investigations performed all over the world, the exact mechanism of acantholysis has not been fully elucidated. Recent studies point out at proinflammatory cytokines such as TNF-alpha, IL-1, or IL-6 as strong players involved in this process. Moreover, experimental studies revealed that synergistic cooperation of pemphigus antibodies with Fas-L and TNF-alpha results in acantholysis. Increased mRNA expression for TNF-alpha and enhanced cytokine's level in serum of PV patients were observed by many authors [2-4]. Furthermore, experimental models showed that mice lacking TNF-alpha receptor are less sensitive to pemphigus development after passive transfer of pemphigus antibodies [2]. The above data at least in part explain therapeutic efficacy of anti-TNF-alpha antibodies in pemphigus vulgaris treatment [5, 6].
###end p 5
###begin p 6
###xml 748 757 748 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pemphigus</italic>
Despite extensive research, the objective criteria of complete cure in PV have not been defined so far. Direct immunofluorescence (DIF) test detecting in vivo IgG deposits bound in the intercellular spaces of the epidermis and indirect immunofluorescence (IIF) test demonstrating circulating IgG antibodies are routine examinations in pemphigus diagnosis and their negative findings may indicate treatment cessation. In some cases, however, despite a long-lasting treatment and lack of clinical symptoms, either both immunological examinations are still positive, or DIF test is negative, but circulating antibodies are still detected. It seems controversial, especially because most dermatologists assume a strong correlation between the titre of pemphigus antibodies and the disease activity. Most studies on PV pathogenesis are focused on immunological disturbances in active stage of the disease.
###end p 6
###begin p 7
###xml 74 79 74 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 307 315 303 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pemphigu</italic>
###xml 102 110 <span type="species:ncbi:9606">patients</span>
Thus, the aim of our study was to evaluate the serum concentration of TNF-alpha, IL-1, and IL-6 in PV patients both in active stage of the disease and in clinical remission and assess their potential influence on disease course. We also assessed the correlation between cytokines' serum levels and titer of pemphigu s antibodies.
###end p 7
###begin title 8
2. MATERIAL AND METHODS
###end title 8
###begin p 9
###xml 696 697 696 697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 54 62 <span type="species:ncbi:9606">patients</span>
###xml 120 128 <span type="species:ncbi:9606">patients</span>
###xml 172 180 <span type="species:ncbi:9606">patients</span>
###xml 512 520 <span type="species:ncbi:9606">patients</span>
The study group consisted of 19 sera obtained from PV patients in active stage of the disease and 24 sera obtained from patients in clinical remission. Sera from active PV patients had been collected before immunosuppressive treatment; (prednisone+cyclophosphamide) was introduced. 19 sera taken from healthy unrelated subjects, age and sex matched served as controls. Pemphigus vulgaris diagnosis was based on the clinical picture and results of histological and immunological examinations. The sera of all the patients and individuals from the control group were examined by IIF on commercially available substrate of monkey esophagus (Euroimmune, Lubeka, Germany), using a standard procedure [7]. The same sera samples were examined by ELISA (MESACUP Desmoglein Test Dsg1 and Dsg3; MBL Co. Ltd, Nagoya , Japan) according to the manufacturer's instruction. ELISA index was assessed as positive when it was higher than cutoff (for Dsg 1-14; for Dgs 3-7).
###end p 9
###begin p 10
###xml 8 16 <span type="species:ncbi:9606">patients</span>
###xml 415 423 <span type="species:ncbi:9606">patients</span>
All the patients' direct immunofluorescence (DIF) tests revealed in vivo IgG and/or C3 deposits bound in the intercellular spaces of the epidermis. Active stage of the disease was considered when all the examinations were positive, blisters and erosions on the mucous membranes and/or skin were present. Sera samples were taken before introducing immunosuppressive treatment. Clinical remission was considered when patients were treated with prednisone (20-40 mg every other day) and cyclophosphamide (50 mg every other day) and demonstrated lack of clinical lesions for at least six months, while DIF and IIF still gave positive results.
###end p 10
###begin p 11
###xml 46 51 46 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
The same sera samples were used to measure TNFalpha, IL-1, and IL-6 levels using commercially available ELISA kits (R & D, Minneapolis, Minn, USA), according to manufacturer's procedure.
###end p 11
###begin title 12
3. STATISTICAL ANALYSIS
###end title 12
###begin p 13
###xml 854 855 854 855 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Statistical analysis was performed using Statistica v.0.5 and GraphPad Prism v.4.03. As laboratory data did not fit a Gaussian distribution according to Shapiro-Wilk test, all results were expressed as median (50th) and interquartile range (25th-75th), and nonparametric tests were used to test statistical significance. To avoid errors inherent in repeated application of Mann-Whitney U tests, the Kruskal-Wallis test was performed to make simultaneous comparison of the assay data from each group, and to determine whether there was a significant variation in the medians of the groups analysed. If this achieved 95% significance, Dunn's multiple comparison posttest was then used to compare the assay results of one group with the other. For correlation studies, the Pearson's correlation or Spearman's rank correlation was used. In all calculations, P < .05 was regarded as statistically significant.
###end p 13
###begin title 14
4. RESULTS
###end title 14
###begin p 15
###xml 54 63 54 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pemphigus</italic>
###xml 85 93 <span type="species:ncbi:9606">patients</span>
###xml 218 226 <span type="species:ncbi:9606">patients</span>
Indirect immunofluorescence test revealed circulating pemphigus antibodies in all PV patients. In the subjects from active stage of the disease, antibodies titers ranged from 1:80 to 1:2560 (median 1:640) while in the patients from remission group from 1:20 to 1:1280 (median 1:80).
###end p 15
###begin p 16
###xml 51 56 51 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 103 110 99 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab1">Table 1</xref>
###xml 123 124 119 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">1</xref>
###xml 125 126 121 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">3</xref>
###xml 689 694 685 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 77 85 <span type="species:ncbi:9606">patients</span>
###xml 164 172 <span type="species:ncbi:9606">patients</span>
Median serum concentrations of IL-1, IL-6, and TNF-alpha in all the examined patients are presented in Table 1 and Figures 1-3. IL-1 serum concentrations in the PV patients from active and remission groups did not significantly differ from the controls. IL-1 concentration in the PV remission group was higher than in the PV active group, however, this did not reach statistical significance. Serum IL-6 concentrations in PV active and PV remission group were significantly higher when compared to the controls. IL-6 levels presented slightly higher values in the active group in comparison to the remission group, but the difference also did not reach statistical significance. Serum TNF-alpha levels did not differ significantly between PV active group, PV remission group and the control. The obtained values also did not differ between PV active and PV remission groups.
###end p 16
###begin p 17
###xml 122 123 122 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 123 124 123 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 123 124 123 124 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>p</italic></sub>
###xml 133 134 133 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 147 155 147 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figure 4</xref>
###xml 332 337 332 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 354 359 350 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 72 80 <span type="species:ncbi:9606">patients</span>
###xml 199 207 <span type="species:ncbi:9606">patients</span>
A significant correlation between serum IL-1 and IL-6 concentrations in patients presenting active stage of PV was found (rp = 0.46; P < .05) (see Figure 4). No similar relation was observed for the patients in the remission stage of PV. We also did not find any significant correlations between serum concentration of IL-1 and TNF-alpha or IL-6 and TNF-alpha in all the studied groups.
###end p 17
###begin p 18
###xml 57 66 57 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pemphigus</italic>
###xml 174 179 174 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 249 250 245 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 250 251 246 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S</italic>
###xml 250 251 246 247 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>S</italic></sub>
###xml 264 265 260 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 214 222 <span type="species:ncbi:9606">patients</span>
When analysing correlations between titer of circulating pemphigus antibodies and serum concentrations of the examined cytokines, we found a negative correlation between TNF-alpha level and antibodies titer in the patients from the remission group (rS = -0.47303; P < .02).
###end p 18
###begin title 19
5. DISCUSSION
###end title 19
###begin p 20
###xml 327 336 327 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pemphigus</italic>
###xml 712 713 712 713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 715 716 715 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 1235 1237 1235 1237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 1410 1412 1410 1412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 1435 1444 1435 1444 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pemphigus</italic>
###xml 1758 1760 1758 1760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 1013 1021 <span type="species:ncbi:9606">patients</span>
###xml 1295 1303 <span type="species:ncbi:9606">patients</span>
###xml 1470 1474 <span type="species:ncbi:10090">mice</span>
Pemphigus vulgaris is a life-threatening disease of autoimmune background. During last decades, its pathogenesis has been widely investigated and new insight into mechanisms triggering disease development and production of antibodies has been recognised. Despite the fact of that detection of circulating and bound in vivo IgG pemphigus antibodies is that main immunological feature, current knowledge point out at involvement not only humoral but also cellular immunological response in pemphigus development. It was shown that Dsg3-specific lymphocytes T proliferate under desmoglein 3 stimulation release Th2-dependent cytokines such as IL-4 and IL-10 and demonstrate ability to modulate activity of B cells [8, 9]. Although it is obvious that autoimmune response in PV is T cell-mediated, the exact role of those cells in acantholysis development has not been elucidated yet. IL-2 is one of the main activators of T lymphocytes. Increased values of soluble receptor for IL-2 (sIL-2R) were detected in sera of patients with pemphigus, and these values correlated with activity of the disease. However, their concentrations were significantly higher in blister fluid thus suggesting presence of activated T cells in PV skin lesions [10]. It was also proven that isolated T lymphocytes from PV patients are required for induction of histological and immunological phenomena in the animal models of pemphigus [11]. Passive transfer of pemphigus antibodies into hairless mice genetically thymus deficient caused their binding in intercellular spaces of the epidermis, however blister formation over the basement layer of epidermis was observed in less than 20% of cases. It is another proof for an important role of lymphocytes T in acantholysis development [12].
###end p 20
###begin p 21
###xml 106 111 106 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 117 122 113 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 328 329 320 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 331 333 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 350 352 342 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 392 397 384 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 631 632 619 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 634 635 622 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 710 715 698 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 775 780 759 760 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 789 794 769 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 873 882 849 858 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pemphigus</italic>
###xml 1018 1023 994 995 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 1036 1041 1008 1009 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 1054 1056 1022 1024 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 53 61 <span type="species:ncbi:9606">patients</span>
###xml 451 459 <span type="species:ncbi:9606">patients</span>
###xml 911 919 <span type="species:ncbi:9606">patients</span>
Keratinocytes stimulated with serum obtained from PV patients presented higher expression of mRNA for IL-1alpha, TNF-alpha, and urokinase plasminogen activator (uPA) and developed acantholysis. When antibodies against these proteins were used in these experiments, the authors observed a significant inhibition of acantholysis [2, 13]. Alecu et al. [14] found increased levels of ICAM-1, TNF-alpha, and IL-6 in sera and blister fluid obtained from PV patients. The above results seem to at least in part confirm the role of these proteins in PV development. Similar results were obtained by D'Auria et al. and Lopez-Robles et al. [3, 4] who showed increased serum levels and in situ expression of IL-6 and TNF-alpha. In experimental models, it was also demonstrated that IL-1alpha and TNF-alpha were able to activate C3 mRNA in keratinocytes culture after stimulation with pemphigus antibodies obtained from PV patients. This phenomenon is strongly inhibited after subsequent incubation of keratinocytes with anti-TNF-alpha and anti-IL1alpha antibodies [15].
###end p 21
###begin p 22
###xml 16 17 16 17 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 174 179 174 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 469 474 465 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 1062 1064 1054 1056 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 1066 1068 1058 1060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 1309 1314 1301 1302 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 1349 1350 1337 1338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 1357 1362 1345 1346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 1536 1538 1520 1522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 1539 1541 1523 1525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 1548 1553 1532 1533 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 1802 1804 1782 1784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 1830 1835 1810 1811 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 1945 1954 1921 1930 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pemphigus</italic>
###xml 2370 2375 2346 2347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 222 230 <span type="species:ncbi:9606">patients</span>
###xml 312 320 <span type="species:ncbi:9606">patients</span>
###xml 511 519 <span type="species:ncbi:9606">patients</span>
###xml 565 573 <span type="species:ncbi:9606">patients</span>
###xml 826 834 <span type="species:ncbi:9606">patients</span>
###xml 1866 1874 <span type="species:ncbi:9606">patients</span>
###xml 2417 2425 <span type="species:ncbi:9606">patients</span>
D'Auria et al. [3] also showed a positive correlation between serum concentration of these cytokines and the number of skin lesions. In our study, we attempted to assess TNF-alpha, IL-1, and IL-6 sera concentrations in PV patients being either in the active stage of the disease or in clinical remission. In the patients presenting the active stage of the disease, only IL-6 serum concentration was significantly higher when compared to the control group. IL-1 and TNF-alpha serum levels did not differ between patients in the active stage and the controls. In the patients who were in clinical remission, we found similar results. Only IL-6 serum level was higher while the rest of the examined cytokines presented similar values to the controls. Decreased levels of IL-6 in remission stage of PV when compared to the active patients (statistically insignificant) may result from the immunosuppressive treatment administration. In many reports, it is noted that prednisone and cyclophosphamide influence proinflammatory cytokines levels, including IL-6 levels [16, 17]. Our results confirm the role of IL-6 in PV pathogenesis, not only in the initial stage of the disease development but also the pathophysiological process maintenance. In most published studies, the authors found an increased level of TNF-alpha in the active stage of pemphigus [4]. TNF-alpha is a cytokine involved in the majority of inflammatory processes, and its increased activity is found in many skin diseases including psoriasis, SLE, or systemic sclerosis [18-20]. TNF-alpha is released by cells under various stimuli including bacterial infections or ultraviolet radiation. It plays a role in many biological processes, enhances phagocytosis, cytotoxicity, and modulates activity of other cytokines such as IL-1 and IL-4 [21]. We did not confirm TNF-alpha increased concentration in PV patients when compared to the controls. However, its negative correlation with pemphigus antibodies titer and relatively increased values when compared to the controls (no statistical significance) may suggest its involvement in maintaining pathological mechanisms. Treatment with immunosuppressive agents is sufficient to reduce skin lesions formation and decrease antibodies production, however it probably does not influence disturbed cellular response. These data also partially explain why anti-TNF-alpha treatment is successful in refractory PV patients.
###end p 22
###begin p 23
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 152 157 152 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 166 170 162 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 451 453 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 474 476 467 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 790 792 783 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 68 76 <span type="species:ncbi:9606">patients</span>
###xml 228 236 <span type="species:ncbi:9606">patients</span>
###xml 595 603 <span type="species:ncbi:9606">patients</span>
###xml 666 674 <span type="species:ncbi:9606">patients</span>
###xml 880 888 <span type="species:ncbi:9606">patients</span>
###xml 1033 1041 <span type="species:ncbi:9606">patients</span>
There is only a scarcity of data on cytokines' levels in sera of PV patients in clinical remission. Bhol et al. [22] revealed a marked reduction of IL-1alpha and IL-1beta with simultaneously increased levels of IL-1R in sera of patients in clinical remission. Intravenous immunoglobulin (IVIG) therapy caused similar effects thus suggesting that its therapeutic effect could depend on modulation of IL1 isoforms and its receptor levels. Galle et al. [23] and Keskin et al. [17] revealed also that IVIG exerts anti-IL-6 properties thus to some extent, explaining mechanisms of its activity in PV patients. IL-10 concentration in serum was also significantly lower in patients in clinical remission when compared to the active ones and its values correlated with pemphigus antibodies titers [24]. To the best of our knowledge, there is no data on IL-6 serum concentration in the PV patients in clinical remission. Our data suggest the role of IL-6 in the immunological disturbances maintenance in remission stage of PV, namely, in the patients in whom, despite lack of clinical lesions, antibodies are still produced and possess the ability to bind to keratinocytes surface antigens. We believe that this observation suggests clinical application of anti-IL-6 antibodies in refractory cases of pemphigus vulgaris.
###end p 23
###begin title 24
ACKNOWLEDGMENTS
###end title 24
###begin p 25
This study was funded by the Polish Scientific Committee and Medical University of Lodz research Projects no. 2P05B07727 and no. 503-1019-1.
###end p 25
###begin article-title 26
Pemphigus-diseases of antidesmosomal autoimmunity
###end article-title 26
###begin article-title 27
###xml 48 53 48 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 80 85 76 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 127 132 119 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 159 164 147 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
In vitro and in vivo expression of interleukin-1alpha and tumor necrosis factor-alpha mRNA in pemphigus vulgaris: interleukin-1alpha and tumor necrosis factor-alpha are involved in acantholysis
###end article-title 27
###begin article-title 28
###xml 100 105 100 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 25 33 <span type="species:ncbi:9606">patients</span>
Cytokines in the sera of patients with pemphigus vulgaris: interleukin-6 and tumour necrosis factor-alpha levels are significantly increased as compared to healthy subjects and correlate with disease activity
###end article-title 28
###begin article-title 29
###xml 3 8 3 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
TNFalpha and IL-6 are mediators in the blistering process of pemphigus
###end article-title 29
###begin article-title 30
###xml 84 89 84 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
Synergistic actions of pemphigus vulgaris IgG, Fas-ligand and tumor necrosis factor-alpha during induction of basal cell shrinkage and acantholysis
###end article-title 30
###begin article-title 31
###xml 100 105 100 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab
###end article-title 31
###begin article-title 32
###xml 63 71 <span type="species:ncbi:9606">patients</span>
Demonstration of skin antibodies in sera of pemphigus vulgaris patients by indirect immunofluorescence staining
###end article-title 32
###begin article-title 33
###xml 89 93 89 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 94 95 91 92 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8727;</sup>
Detection of low avidity desmoglein 3-reactive T cells in pemphigus vulgaris using HLA-DRbeta1*0402 tetramers
###end article-title 33
###begin article-title 34
###xml 71 79 <span type="species:ncbi:9606">patients</span>
Development and characterization of desmoglein-3 specific T cells from patients with pemphigus vulgaris
###end article-title 34
###begin article-title 35
Ligation of CD28 on resting T cells by its ligand B7 results in the induction of both Th1- and Th2-type cytokines
###end article-title 35
###begin article-title 36
###xml 2 7 <span type="species:ncbi:10090">mouse</span>
###xml 105 109 <span type="species:ncbi:10090">mice</span>
A mouse model of pemphigus vulgaris by adoptive transfer of naive splenocytes from desmoglein 3 knockout mice
###end article-title 36
###begin article-title 37
###xml 82 87 <span type="species:ncbi:9606">human</span>
###xml 111 120 <span type="species:ncbi:10090">nude mice</span>
A model for the study of autoimmune diseases applied to pemphigus: transplants of human oral mucosa to athymic nude mice binds pemphigus antibodies in vivo
###end article-title 37
###begin article-title 38
###xml 55 60 55 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 69 74 65 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
Urokinase plasminogen activator mRNA is induced by IL-1alpha and TNF-alpha in in vitro acantholysis
###end article-title 38
###begin article-title 39
###xml 20 25 20 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 85 93 <span type="species:ncbi:9606">patients</span>
ICAM-1, ELAM-1, TNF-alpha and IL-6 in serum and blister liquid of pemphigus vulgaris patients
###end article-title 39
###begin article-title 40
###xml 93 98 93 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 107 112 103 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
In vitro C3 mRNA expression in pemphigus vulgaris: complement activation is increased by IL-1alpha and TNF-alpha
###end article-title 40
###begin article-title 41
The effect of methylprednisolone pulse treatment on cytokine network in graves ophthalmopathy
###end article-title 41
###begin article-title 42
###xml 40 48 <span type="species:ncbi:9606">patients</span>
Cytokine profiles in pemphigus vulgaris patients treated with intravenous immunoglobulins as compared to conventional immunosuppressive therapy
###end article-title 42
###begin article-title 43
###xml 13 18 13 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 42 47 38 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 64 69 56 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
Interleukin 1alpha, tumor necrosis factor alpha, and interferon gamma in psoriasis
###end article-title 43
###begin article-title 44
###xml 97 105 <span type="species:ncbi:9606">patients</span>
Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients
###end article-title 44
###begin article-title 45
Cytokine production and serum levels in systemic sclerosis
###end article-title 45
###begin article-title 46
###xml 59 64 59 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human keratinocytes are a source for tumor necrosis factor alpha: evidence for synthesis and release upon stimulation with endotoxin or ultraviolet light
###end article-title 46
###begin article-title 47
Pemphigus vulgaris: the role of IL-1 and IL-1 receptor antagonist in pathogenesis and effects of intravenous immunoglobulin on their production
###end article-title 47
###begin article-title 48
High levels of neutralizing IL-6 autoantibodies in 0.1% of apparently healthy blood donors
###end article-title 48
###begin article-title 49
###xml 61 69 <span type="species:ncbi:9606">patients</span>
Presence of interleukin 10 in the serum and blister fluid of patients with pemphigus vulgaris and pemphigoid
###end article-title 49
###begin p 50
###xml 57 65 <span type="species:ncbi:9606">patients</span>
Interleukin-1 (IL-1) concentration in serum samples from patients with active stage of pemphigus vulgaris (PV active), remission stage of PV (PV remission), and in normal controls. Box plots with upper and lower bars showing the data range, and upper, middle, and lower lines in the box showing 75th, 50th (median), and 25th centiles, respectively.
###end p 50
###begin p 51
###xml 393 394 393 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 457 458 457 458 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 57 65 <span type="species:ncbi:9606">patients</span>
Interleukin-6 (IL-6) concentration in serum samples from patients with active stage of pemphigus vulgaris (PV active), remission stage of PV (PV remission), and in normal controls. Box plots with upper and lower bars showing the data range, and upper, middle, and lower lines in the box showing 75th, 50th (median), and 25th centiles, respectively. Kruskal-Wallis test across all three groups P < .0001. Only significant Dunn's multiple comparison posttest p values between groups are shown.
###end p 51
###begin p 52
###xml 22 27 22 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 33 38 29 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 76 84 <span type="species:ncbi:9606">patients</span>
Tumor necrosis factor-alpha (TNF-alpha) concentration in serum samples from patients with active stage of pemphigus vulgaris (PV active), remission stage of PV (PV remission), and in normal controls. Box plots with upper and lower bars showing the data range, and upper, middle, and lower lines in the box showing 75th, 50th (median), and 25th centiles, respectively.
###end p 52
###begin p 53
###xml 61 69 <span type="species:ncbi:9606">patients</span>
Correlation between serum concentrations of IL-1 and IL-6 in patients with active stage of PV.
###end p 53
###begin p 54
###xml 70 75 70 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 81 86 77 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 125 133 <span type="species:ncbi:9606">patients</span>
Interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) concentrations in serum samples from patients with active stage of pemphigus vulgaris (PV active), remission stage of PV (PV remission), and in normal controls.
###end p 54

